Navigation Links
Orexigen(R) Therapeutics Announces Proposed Public Offering of Common Stock
Date:7/22/2009

SAN DIEGO, July 22 /PRNewswire-FirstCall/ -- Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced that it intends to offer, subject to market and other conditions, 9,000,000 shares of its common stock in an underwritten public offering. In connection with this offering, Orexigen expects to grant to the underwriter a 30-day option to purchase up to an additional 1,350,000 shares of common stock to cover overallotments, if any. All of the shares are being offered by Orexigen. Leerink Swann LLC is acting as sole book-running manager for the offering.

The securities described above are being offered by Orexigen pursuant to a registration statement previously filed and declared effective by the Securities and Exchange Commission. A prospectus supplement relating to the offering will be filed with the Securities and Exchange Commission. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction. When available, copies of the prospectus supplement and the accompanying prospectus relating to this offering may be obtained from Leerink Swann LLC , Attention: Syndicate Department, One Federal Street, 37th Fl., Boston, MA 02110 or by calling Leerink Swann LLC, toll free, at 1-800-808-7525, Ext. 4814.

About Orexigen(R) Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead investigational product, Contrave(R), has completed Phase 3 clinical trials and is on track for a regulatory submission with the FDA in the first half of 2010. The Company's second product, Empatic(TM), is in the later stages of Phase 2 clinical development, with results expected in the second half of 2009. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss, through combination therapeutic approaches. Further information about the Company can be found at http://www.orexigen.com.


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Orexigen(R) Therapeutics Announces Webcast of Third Quarter Financial Results on November 6, 2008
2. Orexigen(R) Therapeutics to Speak at J.P. Morgan Healthcare Conference
3. Orexigen(R) Therapeutics Names Patrick Mahaffy to Board of Directors
4. Orexigen(R) Therapeutics Names Michael Narachi, 24-Year Biopharmaceutical Veteran, New President and Chief Executive Officer
5. Orexigen(R) Therapeutics Announces In-Licensing of Key Patents to Further Strengthen its Intellectual Property Estate for Contrave(R)
6. Prime Therapeutics Receives TIPPS Certification
7. Adams Respiratory Therapeutics to Celebrate 10th Anniversary of its Incorporation on September 12
8. Transition Therapeutics Announces Fiscal 2007 Year End Financial Results
9. Lorus Therapeutics announces election of three new Directors and appoints a new Chairman
10. Deane F. Johnson Center for Neurotherapeutics to Launch First Mobile Medical Unit on October 4th
11. Russell Investment Group Advises Protalix Biotherapeutics of Index Adjustment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... ... January 24, 2017 , ... ... the expansion of its Medication Counseling Centers to address market needs. To support ... MCC staff by more than 60 percent over the past 6 months. The ...
(Date:1/24/2017)... ... January 24, 2017 , ... In comments ... Research Institute (PCORI) for developing a data access and sharing policy. The nation’s ... data sharing plan as part of award applications, and earmarking specified amounts of ...
(Date:1/24/2017)... ... January 24, 2017 , ... The ... the Annual Enrollment Period (AEP) and the Open Enrollment Period (OEP). 2016 was ... coverage. Mainly, people are witnessing higher deductibles, rising premiums, and few choices with ...
(Date:1/24/2017)... ... January 24, 2017 , ... PeroxyChem Food and Beverage Safety ... (PACE), at the International Production and Processing Expo (IPPE) in Atlanta, Georgia from ... technology that is used in poultry processing facilities to provide constant, real-time data ...
(Date:1/24/2017)... ... January 24, 2017 , ... Manzo Pharmaceuticals, LLC., announced that ... Trademark by the United States Patent and Trademark Office. The purpose of ... consumers into thinking that other products are similar to the patented Lacto-Freedom Probiotic. ...
Breaking Medicine News(10 mins):
(Date:1/24/2017)... Research and Markets has announced the addition ... - Forecast to 2025" report to their offering. ... Global Optogenetics Market is ... next decade to reach approximately $76.24 million by 2025. ... growing count of labs using optogentic techniques for neurosciences, quick growth ...
(Date:1/24/2017)... -- For today, Stock-Callers.com scans the following Biotechnology ... Biopharmaceuticals Inc. (NASDAQ: ALDR ), BioDelivery Sciences International ... EGLT ). These equities are part of the ... rd , 2017, with the NYSE Health Care Index dropping ... S&P 500 also were down 0.3% as a group. These ...
(Date:1/24/2017)... INTRODUCTION Injectable drug delivery systems have ... vials to prefilled syringes, auto-injectors, pen injectors and ... preferred devices for parenteral administration of drugs. Specifically, ... strongly over the past several years. A growing ... format for delivering drugs. The popularity of prefilled ...
Breaking Medicine Technology: